Hypertrophic Cardiomyopathy (HCM) is the most common monogenic cardiovascular disorder, affecting approximately 1 in 500 individuals. It remains the leading cause of sudden cardiac death (SCD) in young people and athletes. While often identified by a dramatic "thickened heart," the clinical reality of HCM involves a complex interplay of genetic mutations, microvascular ischemia, and lethal arrhythmias.

1. The Pathological Architecture

HCM is characterized by left ventricular hypertrophy (LVH) that cannot be explained solely by abnormal loading conditions (like hypertension or aortic stenosis). The hallmark of the disease is myocyte disarray—where the normal parallel alignment of cardiac muscle cells is replaced by a disorganized, "star-shaped" pattern. This structural chaos provides the perfect substrate for re-entrant ventricular arrhythmias.

Obstructive vs. Non-Obstructive

In roughly 70% of patients, the hypertrophy involves the basal septum, leading to Left Ventricular Outflow Tract (LVOT) Obstruction. This is often exacerbated by Systolic Anterior Motion (SAM) of the mitral valve, where the mitral leaflets are sucked into the outflow tract during contraction, further blocking blood flow and causing significant mitral regurgitation.

2. Clinical Clues: The Murmur and the ECG

Identifying HCM in a physical exam requires dynamic maneuvers. The classic murmur is a harsh crescendo-decrescendo systolic murmur heard best at the left lower sternal border.

• Valsalva Maneuver/Standing: Decreases preload $\rightarrow$ increases obstruction $\rightarrow$ Murmur gets Louder.
• Squatting/Leg Raise: Increases preload $\rightarrow$ pushes the septum away from the valve $\rightarrow$ Murmur gets Softer.

On the ECG, look for high-voltage QRS complexes (LVH) and "dagger-like" Q-waves in the lateral leads (I, aVL, V5, V6), which represent the abnormal septal depolarization.

3. Risk Stratification: Who Needs an ICD?

Determining which patient requires an Implantable Cardioverter Defibrillator (ICD) is the most critical task in HCM management. We use the HCM Risk-SCD Calculator, which considers:

1. Maximum Wall Thickness: Massive hypertrophy (≥ 30 mm) is a major risk factor.
2. Family History: SCD in a first-degree relative under age 40.
3. Unexplained Syncope: Especially if recent and not vasovagal.
4. Non-Sustained Ventricular Tachycardia (NSVT): Caught on Holter monitoring.
5. Abnormal Blood Pressure Response: Failure of BP to rise during exercise testing.

4. The Physics of Obstruction: Bernoulli's Principle

To quantify the severity of the LVOT obstruction, we use the simplified Bernoulli equation to convert velocity (measured by Doppler) into a pressure gradient:

Where $\Delta P$ is the pressure gradient in mmHg and $v$ is the peak velocity in m/s. A resting or provoked gradient ≥ 30 mmHg is the threshold for defining obstructive HCM, while ≥ 50 mmHg is typically the threshold for considering invasive septal reduction therapies.

5. Management: From Beta-Blockers to Myomectomy

The goal of therapy is to decrease the heart rate and increase diastolic filling time to minimize the obstruction.

• First-Line: Beta-blockers (like Metoprolol) or non-dihydropyridine calcium channel blockers (like Verapamil).
• Avoid: Diuretics (which decrease preload) and Nitrates/PDE5-inhibitors (which decrease afterload), as both can worsen the obstruction.
• Invasive Options: For refractory symptoms, Septal Myomectomy (surgical removal of part of the septum) or Alcohol Septal Ablation (inducing a controlled "mini-MI" in the septum) are highly effective.